Gene expression in X-TSK overexpressing embryos
| Sample /probe . | Normal . | Expanded or ectopic . | Diminished . | |
|---|---|---|---|---|
| X-TSK 250 pg | ||||
| Sox9 | 8 | 0 | 5 | |
| Sox2 | 3 | 10 | 1 | |
| XK81 | 5 | 0 | 6 | |
| X-TSK 500 pg | ||||
| Sox9 | 1 | 0 | 6 | |
| Sox2 | 4 | 1 | 0 | |
| Xslug | 5 | 0 | 14 (73.7%) | |
| Xbmp4 | 6 | 22 (78.6%) | 0 | |
| Xrx1 | 9 | 17 (60.7%) | 2 | |
| Xotx2 | 14 | 35 (71.4%) | 0 | |
| Six3 | 3 | 22 (88.0%) | 0 | |
| X-TSK 1 ng | ||||
| Sox9 | 11 | 0 | 41 (78.8%) | |
| Xslug | 3 | 0 | 22 (88.0%) | |
| Sox2 | 11 | 44 (80.0%) | 0 | |
| Xbmp4 | 16 | 22 (57.9%) | 0 | |
| XK81 | 7 | 0 | 26 (78.8%) | |
| N-tubulin | 16 | 1 | 49 (74.2%) | |
| X-ESR-1 | 10 | 22 (57.9%) | 6 | |
| X-delta-1 | 18 | 3 | 60 (74.1%) | |
| MyoD | 26 | 5 | 9 | |
| Hairy2A | 16 | 0 | 39 (70.9%) | |
| Msx-1 | 12 | 0 | 40 (76.2%) | |
| β-gal 500 pg | ||||
| Sox9 | 14 | 0 | 0 | |
| Xslug | 16 | 1 | 1 | |
| Sox2 | 19 | 0 | 0 | |
| Xbmp4 | 62 | 2 | 4 | |
| XK81 | 15 | 0 | 2 | |
| Xrx1 | 37 | 0 | 3 | |
| Xotx2 | 14 | 0 | 0 | |
| Six3 | 37 | 1 | 2 | |
| N-tubulin | 28 | 0 | 0 | |
| X-ESR-1 | 35 | 5 | 2 | |
| X-delta-1 | 44 | 0 | 1 | |
| Hairy2A | 38 | 0 | 0 | |
| Msx-1 | 39 | 0 | 0 | |
| X-TSK 1 ng+Su(H)DBM 500 pg | ||||
| Sox9 | 0 | 16 (84.9%) | 3 | |
| Xbmp4 | 7 | 16 (69.6%) | 0 | |
| Su(H)DBM 500 pg | Weakly enhanced | |||
| Sox9 | 15 | 12 | 0 | |
| Su(H)/Ank 500 pg | Weakly enhanced | Weakly diminished | ||
| Sox9 | 11 | 3 | 9 | |
| Xslug | 10 | 4 | 12 | |
| Xbmp4 | 14 | 2 | 7 | |
| X-TSK 1 ng+Su(H)/Ank 500 pg | ||||
| Sox9 | 13 | 0 | 28 (68.3%) | |
| Xslug | 4 | 0 | 32 (88.9%) | |
| Xbmp4 | 18 | 19 (51.3%) | 0 | |
| Sample /probe . | Normal . | Expanded or ectopic . | Diminished . | |
|---|---|---|---|---|
| X-TSK 250 pg | ||||
| Sox9 | 8 | 0 | 5 | |
| Sox2 | 3 | 10 | 1 | |
| XK81 | 5 | 0 | 6 | |
| X-TSK 500 pg | ||||
| Sox9 | 1 | 0 | 6 | |
| Sox2 | 4 | 1 | 0 | |
| Xslug | 5 | 0 | 14 (73.7%) | |
| Xbmp4 | 6 | 22 (78.6%) | 0 | |
| Xrx1 | 9 | 17 (60.7%) | 2 | |
| Xotx2 | 14 | 35 (71.4%) | 0 | |
| Six3 | 3 | 22 (88.0%) | 0 | |
| X-TSK 1 ng | ||||
| Sox9 | 11 | 0 | 41 (78.8%) | |
| Xslug | 3 | 0 | 22 (88.0%) | |
| Sox2 | 11 | 44 (80.0%) | 0 | |
| Xbmp4 | 16 | 22 (57.9%) | 0 | |
| XK81 | 7 | 0 | 26 (78.8%) | |
| N-tubulin | 16 | 1 | 49 (74.2%) | |
| X-ESR-1 | 10 | 22 (57.9%) | 6 | |
| X-delta-1 | 18 | 3 | 60 (74.1%) | |
| MyoD | 26 | 5 | 9 | |
| Hairy2A | 16 | 0 | 39 (70.9%) | |
| Msx-1 | 12 | 0 | 40 (76.2%) | |
| β-gal 500 pg | ||||
| Sox9 | 14 | 0 | 0 | |
| Xslug | 16 | 1 | 1 | |
| Sox2 | 19 | 0 | 0 | |
| Xbmp4 | 62 | 2 | 4 | |
| XK81 | 15 | 0 | 2 | |
| Xrx1 | 37 | 0 | 3 | |
| Xotx2 | 14 | 0 | 0 | |
| Six3 | 37 | 1 | 2 | |
| N-tubulin | 28 | 0 | 0 | |
| X-ESR-1 | 35 | 5 | 2 | |
| X-delta-1 | 44 | 0 | 1 | |
| Hairy2A | 38 | 0 | 0 | |
| Msx-1 | 39 | 0 | 0 | |
| X-TSK 1 ng+Su(H)DBM 500 pg | ||||
| Sox9 | 0 | 16 (84.9%) | 3 | |
| Xbmp4 | 7 | 16 (69.6%) | 0 | |
| Su(H)DBM 500 pg | Weakly enhanced | |||
| Sox9 | 15 | 12 | 0 | |
| Su(H)/Ank 500 pg | Weakly enhanced | Weakly diminished | ||
| Sox9 | 11 | 3 | 9 | |
| Xslug | 10 | 4 | 12 | |
| Xbmp4 | 14 | 2 | 7 | |
| X-TSK 1 ng+Su(H)/Ank 500 pg | ||||
| Sox9 | 13 | 0 | 28 (68.3%) | |
| Xslug | 4 | 0 | 32 (88.9%) | |
| Xbmp4 | 18 | 19 (51.3%) | 0 | |
X-TSK mRNA (250 pg-1 ng), β-gal mRNA (500 pg), other RNAs or their mixtures were injected into unilateral blastomeres at the four-cell stage. Embryos showing identical effects on the injected side were counted at stage 15.